Anthony Berthon

About

Independent Consultant & Interim Manager > PharmD & Health Economist. > Real-World Evidence, Health Economics & Outcomes Research (HEOR), Market Access. > 15+ years with Pharma, Biotech, Medtech and e-Health teams > RWE: evidence-generation strategy & roadmaps, data-source feasibility and landscaping (claims, EHR, registries, national registers), retrospective cohort and chart-review protocols, register-linkage studies, treatment patterns, adherence and persistence, healthcare resource use, burden and cost of illness, epidemiology and target population sizing, external control arms, abstracts, posters, manuscripts. > HEOR: cost-effectiveness and cost-utility models (Markov, partitioned survival, decision tree), budget impact models, cost-consequence and cost-minimisation analyses, global model adaptation to local markets, systematic literature reviews, meta-analyses, indirect treatment comparisons, survival extrapolation, PRO strategy, utility elicitation and mapping (EQ-5D, EORTC QLQ-C30), MCDA frameworks, global value dossiers and value narratives, HTA submissions (HAS/CEESP, NICE, G-BA/IQWiG, TLV, AIFA), EU JCA readiness. > Market Access: market access strategy and integrated la

Experience

Education